Leadiant Biosciences Fined in Spain for Price Gouging Rare Disease Drug

Spain’s Comisión Nacional de Los Mercados y la Competencia (CNMC) has fined Leadiant Biosciences €10.3 million for jumping the price of a therapeutic for the rare disease cerebrotendinous xanthamatosis (CTX). The company is accused by regulators of increasing the cost of chenodeoxycholic acid (CDCA), used to treat CTX, far faster than increases in similar drugs.

According to Tyler Patchen, “However, the regulators are claiming that the company had charged Spain’s National Health System 14 times the price of another nearly identical medicine it had marketed in the country in 2010, costing €984 ($1,019) per package in September of 2010 and increasing to €14,618 ($15,146) per package in 2017.”

To read more, click here.

(Source: Endpoints News, November 15^th, 2022)